Webinars and Sponsored Roundtables — Register Now
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
ARKRAY
| Company | ARKRAY |
|---|---|
| Name of urinalysis instrument | AUTION Eleven AE-40222 |
| Contact | Mariann Amador |
| City, State | Minneapolis, MN |
| Phone | 855-646-3108 |
| Website | |
| Type of instrument | urine chemistry |
| Instrument list price | — (available via purchase) |
| First year instrument sold in the U.S. | 2017 |
| Approximate No. of units in clinical use in the U.S./outside the U.S. | 700/7,200 (worldwide) |
| Foreign countries where company markets instrument | worldwide |
| Country where instrument is designed/manufactured | Japan/Japan |
| Human languages (other than English) supported | — |
| Intended urine sample volume per day | — |
| Dimensions (H×W×D) | 6.5 × 8.3 × 12.9 in. |
| Weight fully loaded with reagents/without reagents | —/7.9 lbs.†† |
| Power requirements | 100–240 VAC (50–60 Hz) |
| Mean time between failure of instrument | 600 days |
| Events that cause instrument to lock or stop analysis | user ID failure, result error |
| • Urine chemistry tests available on instrument in the U.S. | bilirubin (0.5–14.0 mg/dL), hemoglobin (0.03–1.0 mg/dL), glucose (30–1,000 mg/dL), ketone (5–150 mg/dL), leukocyte esterase (25–500 leukocytes/µL), nitrite (0.08–0.5 mg/dL), pH (5–9), protein (10–1,000 mg/dL), specific gravity (1.005–1.030), urobilinogen (2–16 mg/dL) |
| • Color compensation pad included/Flagging thresholds customizable | yes/— |
| • Test strip configuration | loosely packed in bottles |
| • Calibration required after each test strip lot No. change | no |
| • Frequency of customer-performed calibration/Form of calibration | — |
| • How results are displayed for urine chemistry | semiquantitative |
| • Specific gravity correction for protein/glucose | no/no |
| • Microscopy/sediment technology | — |
| • Microscopy/sediment analysis parameters | — |
| • Flagging thresholds customizable | — |
| • Instrument eliminates amorphous crystal interference before sample analysis | — |
| • How results are displayed for microscopy/sediment | — |
| • Reporting format customizable | — |
| • No. of results that can be held in internal memory | — |
| Reagent shelf life/storage temp. for unopened containers of calibrator | — |
| Reagent shelf life/storage temp. for opened containers of calibrator | — |
| Reagent shelf life/storage temp. for unopened containers of control reagent | 547 days/2–8°C |
| Reagent shelf life/storage temp. for opened containers of control reagent | 31 days/2–8°C |
| Reagent barcode-reading capability | yes, for all tests (can read Codabar [NW-7], Code 39, Code 128, PDF 417, ITF) |
| How often quality control samples are run | daily |
| Sample throughput per hour/Time to first result for chemistry | 514/1 min. |
| Sample throughput per hour/Time to first result for microscopy/sediment | — |
| Analyzer has stat mode | no |
| FDA approved for body fluid analysis | no |
| Sample dilutions required for urinalysis/body fluid analysis | no/not applicable |
| Minimum width of sample tube/Minimum length of sample tube | — |
| Conditions or substances that prevent a sample from being run | blood, visible turbidity |
| Means of sample ID entry | barcode scan, manual entry |
| Built-in liquid-level sensing for samples | no |
| Information that can be barcode scanned on instrument | operator identifier, specimen identifier, reagent lot No. |
| Compatible with laboratory automation systems | no |
| How LOINC codes for results are made available | e-mail query |
| Software includes reflex testing/cross-check functionality | — |
| Instrument automatically generates consolidated report* | — |
| Instrument archives patient data | no |
| Instrument connections to transfer information | directly to LIS or via commercial middleware (Data Innovations) |
| Interface standards or formats supported | ASTM 1394-91, ASTM 1381 |
| Bidirectional interface | no |
| Test results can be transmitted to LIS as soon as tests completed | yes |
| Connection to LIS/EHR to upload patient and QC results | LIS: direct serial, hospital network/EHR: option not available |
| Information included in transmission to data-management system | patient ID, specimen ID, result |
| Training included with instrument purchase | no |
| Approximate scheduled maintenance time required | 5 min. daily |
| Onboard diagnostics for troubleshooting | no |
| Provide list of client sites to potential customers on request | no (information is confidential) |
| Clients restricted from sharing their experience with company or software | no |
| Distinguishing instrument features (supplied by company) | proven reliability with less than one unscheduled service event per year; small semiautomated footprint |
| *chemistry and microscopy results in one report; Note: a dash in lieu of an answer means company did not answer; question or question is not applicable | †also sold via distribution partners; ††reagents not kept onboard |